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6 months. The incremental cost-effectiveness ratio (ICER) was determined for 
the cost-effectiveness analysis and comparisons of the three groups with inten-
sive doses (Simvastatin 40 mg/day and Atorvastatin 20-40 mg/day monotherapy 
or combination therapy with Ezetimibe 10 mg) on the provider perspective. The 
direct medical costs were computed by micro-costing method (Reference price in 
2014). The effectiveness was determined by the percentage differences in LDL-C 
reduction. Results: From 250 patients with high risk CHD treated by inten-
sive doses. Sixty-seven, 145 and 38 patients took Simvastatin, Atorvastatin and 
Atorvastatin-Ezetimibe combination, respectively. The outcome determined by the 
percentage differences LDL-C reduction showed that Simvastatin had the lowest 
effectiveness comparing to other groups (mean ± SD; -13.8 ± 32.3%, -28.0 ± 24.8%, 
and -37.8 ± 17.2%, p 0.0001 respectively). ICER determination showed that the 
intensive doses treatment of Atorvastatin had the best result (ICER = 326.91 THB) 
whereas than of Atorvastatin-Ezetimibe combination was poorer (ICER = 732.44 
THB). ConClusions: Comparison of intensive doses Simvastatin, Atorvastatin, 
and Atorvastatin-Ezetimibe combination regimens in second-line treatment 
among high-risk CHD outpatients showed that intensive dose Atorvastatin regi-
men was the most cost-effectiveness.
PCV76
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objeCtives: Utilizing previously published selection criteria1, identify and evaluate 
current literature that is focused on cost-effectiveness of genotype-guided medica-
tion programs for patients at high risk for a thrombotic event. The aim of study is 
to provide the scientific community with a comprehensive, yet brief overview of 
studies that could inform future development of personalized medicine research 
within this subset of cardiovascular disease. Methods: The literature search was 
conducted within PubMed and Web of Science databases. The objective was to iden-
tify studies published from January 2008 (conclusion period of Vegtar’s research) to 
October 2014 that also included the search term “pharmacogenetic” and the term 
“pharmacoeconomic”. Results: Ten articles met inclusion criteria. Genotypes 
CYP2C19, CYP2C9, VKORC1, KIF6 were used alone and/or in combination within 
differing patient populations. Medication programs included (number of papers): 
Warfarin (4), Clopidgrel (including other in-class agents: 2), phenprocoumon (1), 
atorvastatin/pravastatin (1) and Dabigitran (and other in-class agents: 1). The fol-
lowing types of economic evaluations were utilized either alone or in combination: 
CEA, CUA, CUR, CBA, Threshold Analysis, ICER, ICUR, EA, and INB. Outcome meas-
ures and sensitivity analysis were variable and did not always reach thresholds of 
significance within the overall study population. ConClusions: Comprehensive 
study evaluations were lacking due to inconsistent methodology. Specific study 
guidelines for the field of genotype-guided therapy are needed. With multiple block-
buster medications reaching patent expiry, the cost-effectiveness and sensitivity 
analysis from previous years warrant a second evaluation. It is anticipated that 
genotype-guided treatment may be shifting to a cost-effective option for only the 
treatment-resistant, or smaller populations with a differentiated risk status. This is 
in contrast to selecting genotype-driven therapy as an initial option for the masses 
of patients diagnosed with thrombotic event risk in a more traditional “treat every-
one the same” algorithm. 1Stepfan Vegter et. al, “Pharmacoeconomic Evaluations 
of Pharmacogenetic and Genomic Screening Programmes” Pharmacoeconomics 
2008: 26(7) 569-587.
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objeCtives: To assess cost effectiveness of anticoagulant clinics after FDA approval 
of New Oral Anticoagulants (NOACs) for preventing of ischemic stroke in Atrial 
Fibrillation (AF) patients in the United States. Methods: A decision tree was built 
using outcomes data obtained from randomized clinical trials and publicly available 
cost data. The analysis compared the cost effectiveness of 150mg dabigatran twice 
a day taken with no anticoagulation clinic monitoring versus warfarin titrated to 
dose based upon anticoagulation clinic monitoring. The analysis was for one year 
using an institutional perspective. The population in this analysis was a cohort of 
AF patients, ≥ 65 years old, with a mean CHADS2 score of 2, and no contraindication 
to anticoagulation. The primary outcomes measured were cost in US$ and Quality 
Adjusted Life Year (QALY). All data were subject to sensitivity analyses. Results: 
The base case analysis showed that changing from warfarin to dabigatran without 
monitoring resulting in an additional $251,000 per QALY saved. Sensitivity analyses 
found that the model was sensitive to utilities assigned to outcomes and the prob-
ability of death. ConClusions: NOACs claim to reduce the need for anticoagula-
tion monitoring, thereby competing with anticoagulation clinics. This study showed 
that substituting NOACs for warfarin in this population was not within acceptable 
willingness to pay values for new therapies. It is likely that anticoagulation clinics 
will remain a cost effective option in the near future.
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bACKGRound: Atrial fibrillation (AF) is associated with development of thrombo-
embolic events [1]. The standard therapy used in patients with non-valvular atrial 
fibrillation (NVAF) with risk of stroke is Warfarin. There are new oral anticoagulants 
(NOACs) that also are recommended [2]. objeCtives: Evaluate cost-effectiveness 
of Apixaban compared to Oral Anticoagulants in the prevention of thromboembo-
litic events in NVAF patients from perspective of Guatemala’s Public HealthCare 
System (IGSS). Methods: A Markov decision-analysis model was designed using 
data from clinical trials [3,4,5] (indirect comparisons, where appropriate) to evaluate 
lifetime costs and quality-adjusted life-years (QALY) of Apixaban (5mgBID) in com-
parison to Rivaroxaban (20mg/day) and Warfarin (5mg/day). IGSS used Warfarin and 
Rivaroxaban in NVAF patients. The health states evaluated were: ischemic and hem-
orrhagic strokes, hemorrhagic events (intracranial hemorrhage, other major bleeds 
and clinically relevant non major bleeds), systemic embolism (SE) and myocardial 
infarction (MI). The model population was a hypothetical cohort of 70-year-old NVAF 
patients, suitable to Vitamin K antagonist treatment. Only direct medical costs were 
considerate and taken from IGSS databases from 2014 [6,7]. Outcomes were: overall 
cost, QALY and ICER.  Cost and health outcomes were discounted at 5.0% per year, 
using a lifetime horizon. Results: Apixaban is the only therapy that prevents and 
improved all clinical outcomes. Apixaban prevented: 3 Ischemic Strokes, 14 hemor-
rhagic strokes, 71 hemorrhagic events, 1 MI and 3 SE in comparison to Warfarin. 
Overall costs in a lifetime period per patient were US$9,190; US$11,763; US$12,045 
for Warfarin, Apixaban, and Rivaroxaban respectively.  Apixaban earned the high-
est QALY 5.740; Rivaroxaban reported 5.699 and Warfarin 5.570. Used Warfarin as a 
base, the ICER of Apixaban and Rivaroxaban were US$15,135 and US$21,961 respec-
tively. ConClusions: Neither Apixaban nor Rivaroxaban are Cost-Effectiveness 
therapies in comparison with Warfarin according Guatemala’s 3GPB (US$10,400). 
Among the NOACs currently used by IGSS, Apixaban is shown to be a cost-saving 
therapy in comparison to Rivaroxaban.
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objeCtives: To assess the cost-effectiveness of apixaban for the prevention of 
stroke in patients with non valvular atrial fibrillation (NVAF) from the payer’s 
perspective of the Ministry of Public Healthcare in Ecuador (MPHE). Methods: A 
lifetime Markov model was developed to evaluate the pharmacoeconomic impact 
of apixaban compared to aspirin, warfarin, dabigatran in different dosage (110 
mg and 150 mg) and rivaroxaban, in patients with NVAF and risk of stroke. The 
clinical events considered were: stroke, bleeding, myocardial infarction (MI), car-
diovascular hospitalization (CVH), and treatment discontinuation (TD) of which 
the data was obtained from indirect comparisons, published literature and input 
data from a local expert panel. All costs information 2014 (drug and adverse events) 
was obtained from public data sources of the MPHE. Results: In a Cohort of 
1000 patients with NVAF, apixaban avoided 51 ischemic stokes and 3 bleedings 
vs. aspirin, 4 ischemic stokes, 28 bleedings and 11 related deaths vs. warfarin, 
21 ischemic stokes and 4 related deaths vs. dabigatran 110mg, and 11 ischemic 
strokes, 28 bleedings and 5 related deaths vs. dabigatran 150mg and 7 ischemic 
stokes, 7 bleedings and 6 related deaths vs. rivaroxaban. Apixaban was associated 
with 0.324 life years (LYG) and 0.0.273 quality-adjusted life-years (QALYs) gain 
when compared to aspirin, 0.181 LYG and 0.190 QALYs gain compared to warfarin, 
0.123 LYG and 0.106 QALYs gain when compared to dabigatran 110mg, 0.081 LYG 
and 0.07 QALYs gained compared to dabigatran 150mg and 0.059 LYG and 0.048 
QALYs gained compared to rivaroxaban. Apixaban was more effective and less 
costly (dominant) than dabigatran 110mg and dabigatran 150mg and cost-effective 
alternative compared with aspirin, warfarin and rivaroxaban. ConClusions: 
Apixaban is a cost effective or dominant alternative compared with treatment 
options for the prevention of stroke in patients with NVAF from the payer’s per-
spective of the Ecuadorian Ministry of public healthcare.
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oR CaRdioVaSCulaR diSeaSe ReCeiVinG SeCond-line tReatment with 
intenSiVe doSeS of SimVaStatin atoRVaStatin and atoRVaStatin-
ezetimibe Combination in GeneRal PRaCtiCe
Tewthanom K.1, Rattanakunooprakarn H.1, Sakthong P.2
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objeCtives: Current studies have recommended intensive doses of statins in 
patients with diabetes or cardiovascular disease. In general practice, standard 
dose statins, which used to be effective treatment may not be good enough. 
Furthermore, the cost-effectiveness studies have not concerned about this prob-
lem that may be an important factor in cost-effectiveness analysis. The pur-
pose of this study was to determine the cost-effectiveness of intensive doses of 
Simvastatin, Atorvastatin, and Atorvastatin-Ezetimibe combination among high-
risk CHD outpatients in second-line treatments. Methods: A cross-sectional ret-
rospective study in high-risk CHD outpatients was performed at the Chandrubeksa 
Hospital Medical Department of the Royal Thai Air Force, Thailand. Data collection 
was done by computerization combined with reviewing medical record during 
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objeCtives: To evaluate the cost-utility of apixaban vs warfarin in patients 
with atrial fibrillation (AF) from the Peruvian Social Security (EsSalud) perspec-
tive. Methods: A validated Markov decision model was adapted from EsSalud´s 
perspective. For efficacy and safety inputs, the model is based on data from the 
ARISTOTLE trial and clinical trials of warfarin therapy for AF. Resource utilization 
and costing of events were estimated using a reference hospital´s billing records 
and validated with local experts. Costs of procedures were obtained from official 
EsSalud tariffs. The costs of medications were obtained from SEACE. All costs 
are presented at 2014 nuevos soles. A discount rate of 3.5% was used for both 
costs and outcomes. A cohort of 1,000 patients was modeled using a lifetime 
horizon. Probabilistic sensitivity analysis (PSA) as well as univariate sensitivity 
analyses were performed. Results: The following outcomes were estimated: Total 
Ischemic Stroke (non-fatal mild, non-fatal moderate, non-fatal severe, fatal) apixa-
ban: 147 vs. warfarin: 161. Total hemorrhagic stroke (non-fatal mild, non-fatal 
moderate, non-fatal severe, fatal) apixaban: 14 vs. warfarin 26. Other major bleeds 
(non-fatal GI bleeds, non-fatal non ICH or non GI related major bleeds, fatal): 
apixaban: 66 vs. warfarin: 85. Warfarin therapy resulted in a quality-adjusted life 
expectancy of 6.19 years at a cost of S/. 14,744. Treatment with apixaban led to 
a quality-adjusted life expectancy of 6.50 years at a cost of S/. 27,473. The cost-
utility ratio was calculated at S/. 41,296 per QALY. Our findings were robust in 
univariate sensitivity analyses varying model inputs across plausible ranges. In 
Monte Carlo analysis, apixaban was cost-effective in 70% of simulations using the 
recommended threshold for WHO of 3 GDP per capita. ConClusions: Apixaban 
is a cost-effective alternative relative to warfarin for secondary stroke prevention 
in patients with AF treated at EsSalud.
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objeCtives: To assess the cost-effectiveness of monotherapy with a phosphodi-
esterase-5 (PDE-5) inhibitor, an endothelin receptor antagonist (ERA), or a pros-
tanoid versus supportive care in patients with pulmonary arterial hypertension 
(PAH); and, to assess the cost-effectiveness of add-on combination therapy versus 
monotherapy PAH drugs. Methods: A cost utility analysis based on a Markov 
model was designed to estimate costs and efficacy of both PAH monotherapy 
in treatment naïve patients and add-on therapies for treatment experienced 
patients. Separate analyses were conducted by PAH functional class (II, III). The 
primary outcome measure was the number of quality adjusted life years (QALYs) 
associated with treatment. Transition probabilities, based on the relative risk of 
improving and worsening in functional class with treatment versus placebo, were 
derived from a concurrent network meta-analysis. Utility values and costs were 
obtained from published data and clinical expert opinion. Extensive determinis-
tic sensitivity analyses and probabilistic analysis were conducted. Results: For 
monotherapy versus supportive care, in the base case, sildenafil is considered 
the most cost-effective therapy for patients with PAH in functional class II and 
III. Tadalafil was also less costly and more effective than supportive care in func-
tional class II and III; however, sildenafil was dominant over tadalafil. There were 
no studies comparing monotherapy with a PDE-5 inhibitor to add-on therapy. 
At a decision-maker’s willingness to pay of less than ~$88,000 per QALY, neither 
add-on therapy with an ERA plus tadalafil nor add-on therapy with an ERA plus 
riociguat would be considered cost effective in patients with PAH in functional 
class II and III relative to an ERA alone. Despite the uncertainty in the clinical 
inputs, the probabilistic sensitivity analysis showed that apart from sildenafil and 
tadalafil, the other PAH therapies had negligible probability of being the most cost 
effective. ConClusions: Sildenafil is considered the most cost-effective therapy 
for patients with PAH in functional class II and III.
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objeCtives: To characterize Medicare patients with acute ischemic stroke (AIS) 
and describe healthcare resource utilization and associated direct costs during 
one-year pre-admission and follow-up period. Methods: Medicare beneficiaries 
ages 65+ years with an incident AIS hospitalization in 2011 were identified from 
the 5% random Medicare Limited Data Set. Resources utilized and expenditures 
for hospitalizations, ICU stays, outpatient visits, rehabilitation, ER visits, and by 
types of services were measured during five phases: (1) pre-admission; (2) hospi-
talization to one-month; (3) 2- to 3-months; (4) 4- to 6-months; and (5) 7-months 
to 1-year. The differences in the mean annual costs pre- and post-AIS were com-
pared. Results: We identified 6,697 AIS patients (age 79±8.0), 614 (9.2%) who were 
readmitted within 30 days. Resource utilization and costs in all categories were 
highest during the first 30 days and decreased progressively during follow up. The 
average cost per patient during hospitalization to one-month period was $16,219. 
The average cost was $4,588 at 2- to 3-months; $4,650 at 4- to 6-months; and 
$7,426 at 7-months to 1-year period. The average annual cost in the year following 
AIS was $32,882 per patient. The three highest annual average cost drivers were 
diagnostic/lab services ($27,263), followed by inpatient hospitalization ($19,226), 
objeCtives: Venous thromboembolism (VTE), including deep vein thrombo-
sis (DVT) and pulmonary embolism (PE), is a common cardiovascular disorder. 
Acute VTE is typically managed with a short course parenteral anticoagulation 
followed by 3-6 months vitamin-K antagonist. Novel oral anticoagulants do not 
require routine anticoagulation monitoring and dose adjustments, thus poten-
tially providing an alternative treatment option. The cost-effectiveness of dabi-
gatran etexilate vs. edoxaban was evaluated over six months of treatment in the UK 
care setting. Methods: A life-time Markov model was used, evaluating costs and 
quality-adjusted life years (QALY) of recurrent VTE (rVTE) and VTE-related deaths, 
and most common adverse events during anticoagulation treatment, major or clini-
cally relevant bleeds (MCRB). The efficacy and safety of dabigatran were based on 
the pooled RE-COVER treatment studies, and indirectly compared with results of 
The Hokusai Study for edoxaban. Utility estimates for rVTE, bleedings and long-
term consequences of VTE were sourced from RE-COVER studies, and from the 
literature. Costs were analyzed from the perfective of the NHS and PSS. Results: 
Following index VTE, six months treatment with dabigatran etexilate was less costly 
and improved patients’ quality of life when compared with six months edoxa-
ban, assuming equal drug costs. Dabigatran projected more rVTEs overall, but less 
number of non-fatal PEs; dabigatran had less MCRB, hence the additional costs of 
rVTE were compensated by cost savings from avoidance of bleedings. Probabilistic 
sensitivity analyses showed 60% likelihood for dabigatran to be considered cost-
effective at a willingness-to-pay of £30,000. Evaluating the model for treatment 
in a Western-European population, with efficacy and safety from corresponding 
sub-groups of RE-COVER studies, and The Hokusai Study, dabigatran etexilate was 
projected to be less expensive and to improve patients’ quality of life compared with 
edoxaban. ConClusions: Dabigatran etexilate was projected less costly and safer 
than edoxaban when administered for six months following VTE.
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objeCtives: The study objective was to investigate and compare the relative costs 
and effects of using azilsartan medoximil – chlorthalidone, a newly approved com-
bination therapy in comparison to existing olmesartan medoximil – hydrochlor-
thiazide in treating mild to moderate essential hypertension, using the third party 
payer perspective and the risk of developing coronary heart disease (CHD) in 10 
years. Methods: A decision tree analysis was done using Tree Age Pro®. Cost evalu-
ations included direct medical costs i.e. drug cost, cost of medical care (general phy-
sician and specialist visits) and cost to treat the adverse events, hospitalization and 
laboratory services over a time frame of one year. Cost values were obtained from 
the Red book 2010 and literature. Effectiveness was calculated by the reduction in 
SBP which was obtained, from various randomized controlled trials for these drugs. 
Incremental cost effectiveness ratio (ICER) was calculated. Monte Carlo simulation 
and probabilistic sensitivity analysis was done to further validate our findings. 
The risk of getting CHD in the next 10 years was calculated using Framingham risk 
score. Results: Outcomes favored azilsartan (8.51 mm Hg) with a total expected 
cost for treatment as $4759.46 to olmesartan (6.71 mm Hg) with a total cost as 
$4949.48. The ICER was 105.07. Patients on azilsartan have a 12% risk and patients on 
olmesartan have a 26% risk of developing CHD in the next 10 years. ConClusions: 
This study showed that patients with mild/moderate essential hypertension on 
azilsartan have a lower risk of developing CHD when compared to those on olm-
esartan. Azilsartan is a cost effective therapy compared to olmesartan, in treating 
mild/moderate hypertension, from a third party payer perspective.
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objeCtives: It is estimated that up to 400,000 persons in Mexico are hospitalized 
yearly for deep-vein thrombosis (DVT). DVT refers to the presence of a thrombus in 
the deep vein system. The main objective was to compare the treatment costs of 
tinzaparin, enoxaparin and nadroparin of patients with DVT from the institutional’s 
view in Mexico. Methods: We developed a cost-minimization model by using out-
comes and resource utilization data from an indirect treatment comparison (no 
head-to-head trials compare these treatments) of patients with DVT. We found 
that recurrence and major bleeding was equally effective in all the LMWHs. Only 
direct medical costs were used, such as medications and adverse events; these were 
obtained from the portal shop by IMSS and also from their unitary costs. To prove 
the strength of the analysis, deterministic sensitivity analysis was performed; all 
the quantities are expressed in Mexican pesos (MXP) at 2014 Results: Tinzaparin 
sodium showed to be the less expensive LMWH for 10 days treatment of DVT; the 
savings resulted compared with nadroparin and enoxaparin were $670.44 hasta 
$1,111.40 respectively. Tinzaparin sodium reduced 28.48% of nadroparin total cost 
and 40.18% of enoxaparin total cost. ensitivity analysis did not change the con-
clusion that tinzaparium sodium is less expensive than nadroparin and enoxa-
parin (varying patient weight, duration of treatment and considering medication 
waste). ConClusions: Tinzaparin sodium has the highest mean molecular weight 
(approximately 6,500 Da) of the commercially available LMWHs and is least depend-
ent on renal clearance. In addition, tinzaparin sodium strategy is less expensive than 
the LMWHs strategy for the inpatient treatment of DVT in Mexico.
